Results of IVAM chemotherapy in relapsed or refractory non-Hodgkin's Lymphoma.
- Author:
Chi Won SONG
1
;
Jin No PARK
;
Seok Goo CHO
;
Jong Wook LEE
;
Young Seon HONG
;
Woo Sung MIN
;
Chun Choo KIM
;
Kyung Shick LEE
Author Information
1. Catholic Hematopoietic Stem Cell Transplantation Cencer, Catholic University of Korea, Seoul, Korea. y3315@hanmail.net
- Publication Type:Original Article
- Keywords:
IVAM;
Relapsed lymphoma;
Refractory lymphoma;
Mobilization
- MeSH:
Bone Marrow;
Cytarabine;
Disease-Free Survival;
Drug Therapy*;
Etoposide;
Fever;
Follow-Up Studies;
Humans;
Leukocyte Count;
Lymphoma, Non-Hodgkin*;
Multivariate Analysis;
Neutropenia;
Prognosis;
Recurrence;
Risk Factors;
Sepsis;
Stem Cell Transplantation;
Stem Cells;
Thrombocytopenia
- From:Korean Journal of Medicine
2001;61(2):141-150
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Patients with non-Hodgkin's lymphoma who do not respond to first-line chemotherapy or those who relapse after obtaining a complete response have a poor prognosis and are rarely cured with usual salvage chemotherapy. We investigated the treatment responses, toxicities, prognostic factors and mobilization efficacy of peripheral blood stem cells (PBSC) used as salvage chemotherapy. METHODS: 55 patients with refractory (36) or relapsed (19) NHL were treated from Novembr 1997 to October 1999 with IVAM (ifosfamide, etoposide, cytarabine, methotrexate) regimen. Each patients was scheduled to receive one to three cycles of chemotherapy. When the leukocyte count reached 5x109/L after chemotherapy, PBSC collection was performed. The treatment was repeated every 4 weeks. RESULTS: The median age was 48 years (range, 19-76). Median 2.1 cycles of chemotherapy were administered. 15 patients (27.3%) achieved complete response and 29 (52.7%) partial response, with an overall response rate of 80.0%. Myelosuppression was the major toxicity, with 98.2% of grade 3, 4 neutropenia and thrombocytopenia, but there was no serious hemorragic event. Neutropenic fever occurred in 25.5% of the patients with one treatment-related death due to sepsis. Non-hematologic toxicity was modest. PBSC was collected in 36 patients for high dose chemotherapy and autologous stem cell transplantation. The median number of mononuclear cells collected was 9.9x108/kg and the median number of CD34(+) cells collected was 11.9x106/kg. After a median follow-up of 13 months (range, 3-26), median progression free survival were 12 months and median overall survival has not been reached yet. 1-year overall survival and progression free survival were 61.9% and 46.1%, respectively. In univariate analyses, unfavorable prognosis was associated with poor performance status (p=0.001), high LDH (p=0.041), stage III,IV (p=0.04), extralymphatic lesion (p=0.027), B sx (p=0.034), bone marrow involvement (p=0.039) and performing high dose chemotherapy (p=0.005). Multivariate analysis showed that performance status(p=0.0042), B sx(p=0.049) was a significant independent risk factors for death. CONCLUSION: These results suggest that IVAM is an effective salvage chemotherapy for refractory or relapsed NHL and allow effective PBSC collection for high dose chemotherapy and autologous PBSCT.
